NEJM 新英格兰医学杂志· Thomas D. NortonRegeneron Pharmaceuticals, Tarrytown, NYJorg TaubelRichmond Pharmacology, LondonGavin H. ImperatoSonya Aziz-ZamanJane WitkinJutta MillerKusha A. MohammadiShunguang WangTerri SwansonMadison StomsXiping ChengJessica D’AntonioShehla HabibDavid WorkmanJustin ChoYogesh PatelVidya XavierChao ChenDavid J. SmithSean SmithSusana PereiraDonato ForlenzaJoette PindarMeredith CrosbyShawn FidottaMauricio LealFady TaniosViktoria GusarovaMark SleemanJennifer HamiltonJohn DavisDinko Gonzalez TrotterRong LiuBret MusserEd CoxNed BraunsteinNiek VerweijLuca A. LottaGeorge D. YancopoulosAris BarasGary A. HermanDavid J. Ledererfor the ALN-CIDEB-NASH-2486 Study Investigators, Regeneron Genetics Center (RGC), Geisinger Health System–RGC DiscovEHR Collaboration, Penn Medicine Biobank, Colorado Center for Personalized Medicine, Mayo Clinic–RGC Project Generation, Malmö Diet and Cancer Study, Indiana University School of Medicine (Indiana-CLDB), UCLA Health–RGC ATLAS Collaboration, Mount Sinai Million Health Discoveries Program, and the University of Texas Southwestern, Dallas Biobank*Regeneron Pharmaceuticals, Tarrytown, NY·· 5 天前精选AI 评分62
Regeneron 在 NEJM 报告靶向 CIDEB 的 siRNA 用于 MASLD 成人的研究
A Liver-Targeted CIDEB siRNA in Adults with MASLD
AI 导读
Regeneron 研究团队在 NEJM 发表简报，介绍一种靶向 CIDEB 的 siRNA 在 MASLD 成人中的研究，试验代号为 ALN-CIDEB-NASH-2486。目前公开内容仅为在线先发表的摘要，未披露受试者人数、剂量和疗效结果。
推荐理由
这条来自 NEJM 的简报由 Regeneron 研究团队发布，只交代了靶向 CIDEB 的 siRNA 在 MASLD 成人中的研究设计，未给出疗效数据。
来源：NEJM 新英格兰医学杂志 · nejm.org